Immunohistochemical markers for arthritis in psoriasis

D J Veale, L Barnes, S Rogers, O FitzGerald

Abstract

Objectives—To examine the immunohistological features in the involved skin of patients with psoriatic arthritis (PA) \( (n = 15) \), compared with those in involved skin from patients with psoriasis but no arthritis \( (n = 5) \), and with a group with normal skin \( (n = 4) \), to identify markers for arthritis in psoriasis.

Methods—Skin was obtained from patients by 6 mm punch biopsy and normal skin was provided by the department of plastic surgery. Samples were stained with monoclonal antibodies against T cells (CD3, CD8, CD4, CD45Ro), B cells (CD20), macrophages (mac387), vascular endothelium (FVIII-related antigen) and a Langerhan’s cell marker (p155). The number of cells/vessels staining with each monoclonal antibody was calculated and serial sections of skin were examined to estimate the presence of DR+keratinocytes.

Results—There were significantly more CD45Ro T-cells and blood vessels in patients with psoriatic arthritis compared with both psoriasis alone, and with normal controls \( (p<0.02) \). While B-cells were not seen in psoriasis without arthritis or in normal skin, a small but significant number were observed in PA \( (p<0.02) \). Furthermore, while DR+ keratinocytes were present in both psoriatic arthritis and psoriasis skin, there were significantly more DR+ cells in the psoriatic arthritis epidermis compared with psoriasis alone \( (p<0.02) \).

Conclusions—This study suggests that increased numbers of CD45Ro T-cells, greater vascularity, the presence of B-cells, and increased numbers of DR+ epidermal cells are markers for arthritis in patients with psoriasis.

Psoriasis (Ps) is a common, chronic, inflammatory skin disorder which affects 2–3% of the population in Northern Europe.\(^1\) A subgroup of between 5–7% of these patients will have an associated inflammatory arthritis.\(^2\)\(^3\) The reasons for this are not clear and indeed it is not possible to predict which patients will develop an arthritis.

Immunohistological studies in Ps have demonstrated a number of characteristic findings: inflammatory cells, predominantly T lymphocytes, accumulate in the skin,\(^4\)\(^5\) there are prominent microvascular changes\(^6\)\(^7\)\(^8\) and keratinocytes (KCs) become highly activated.\(^9\)\(^10\) The activated T lymphocyte expresses the antigen CD45Ro+, the class II MHC antigen HLA-DR+ and receptors all of which are important molecules in the recognition and binding of antigen peptide.\(^11\) Cell surface markers, including adhesion molecules such as intercellular adhesion molecule (ICAM-1), play important roles in cell-cell recognition, binding and communication necessary in the immune response.\(^12\) In contrast to the previously perceived role of KCs as being uninvolved in the inflammatory process, it is now known that they produce a number of pro-inflammatory cytokines and that they may express both MHC class II HLA-DR antigens as well as ICAM-1.\(^13\)\(^14\) Furthermore, it has been suggested that the presence of HLA-DR+ keratinocytes may be a marker for arthritis in psoriasis.\(^15\)

In this study, a quantitative immunohistological examination of the involved skin from patients with psoriatic arthritis (PA) was undertaken. Results were compared with skin obtained from patients with psoriasis but no arthritis (Ps) and with normal control skin to identify markers for arthritis in psoriasis.

Materials and methods

PATIENT POPULATION

Patients with Ps and PA were recruited from outpatient clinics and as inpatients from the wards of the dermatology and the rheumatology services of the City of Dublin Skin and Cancer Hospital, Beaumont Hospital and St Vincent’s Hospital, Dublin. This ensured that patients with a spectrum of mild to severe skin and joint disease were included in the study. Patients were required to satisfy the criteria of Moll and Wright for the diagnosis of PA;\(^15\) however, patients with a rheumatoid factor titre greater than 1:80 were excluded from the study. Patients who had taken disease-modifying antirheumatic drugs or undergone psoriasis therapy within the three months before assessment were excluded. All patients gave their informed consent, and the study had the approval of the Ethics Committees of all three hospitals.

Skin biopsies were obtained from 15 patients with PA. There were eight females and the mean (range) age was 50 years (21–75). The mean (range) disease duration of psoriasis was 15 years (0–25–50) and of arthritis was seven years (0–25–24). All patients had psoriasis...
vulgaris, eight had an asymmetric oligoarthritis and seven had a symmetrical polyarthritis. Skin biopsies were also obtained from five patients with psoriasis but no arthritis (Ps) and from four normal control subjects. Extent and severity of psoriasis was evaluated in the percentage of skin involved using the rule of 9s. The median (range) in the PA group was 18% (9–72) and in the Ps group was 18% (9–63) demonstrating that no significant difference existed in the skin disease between the two groups. Skin biopsies were obtained before the start of treatment of the skin disease.

CLINICAL ASSESSMENT
All patients were assessed by the same physician (DV). A full history was taken including previous therapy as an outpatient or inpatient. The distribution and percentage of skin involved by psoriasis was recorded and the presence of nail dystrophy and pattern of joint involvement was noted.

TECHNIQUE OF SKIN BIOPSY
Punch biopsy specimens, 6 mm in diameter, were obtained from the edge of a psoriatic plaque using local anaesthesia with 2% lignocaine. Normal control skin was provided by the department of plastic surgery from patients undergoing split skin grafts.

TISSUE PREPARATION
The biopsies were divided into two pieces, one of which was placed on sephadex and snap frozen in liquid nitrogen. Sections 5 μm thick were then cut from the frozen specimens and placed on glass slides. Several sections from each biopsy were placed on each slide to obtain a representative assessment. They were dried at room temperature overnight, wrapped in tin-foil and then stored at −70°C until processed. The remaining biopsy tissue was fixed in formalin and embedded in paraffin for haematoxylin and eosin, plasma cell and mast cell staining. Plasma cells were demonstrated using methyl green pyronin (MGP) stain and mast cells with a uronitrile metachromatic staining method.

IMMUNOHISTOCHEMICAL STAINING TECHNIQUE
Tissue sections stored at −70°C were allowed to thaw at room temperature before being unwrapped. The sections were then fixed in acetone for 10 minutes before staining. The monoclonal antibodies used are shown together with their respective antigens and specificities in table 1.

A standard three-stage immunoperoxidase labelling technique utilising avidin-biotin immunoperoxidase complex (ABC)16 was employed. Colour was developed by immersing the slides in a solution of 0·05% (weight/volume) 3,3′-diaminobenzidine tetrahydrochloride (Sigma, St Louis, MO) and 0·003% hydrogen peroxide in 0·05 M Tris-0·15 M NaCl buffer, pH 7·4. Staining of serial sections of skin was undertaken using anti-HLA-DR, anti-CD3 and the monoclonal p155 which recognises monocyte-derived phagocytic cells17 such as dendritic Langerhan’s cells. A patient was considered to have HLA-DR+ keratinocytes if cells were HLA-DR+ and CD3/p155 negative.

Tonsillar tissue was used for immunohistological controls; the positive controls were processed in exactly the same way as the skin and the primary antibody was replaced by PBS for the negative controls.

MICROSCOPIC EVALUATION
All sections of tissue were examined under 400 × magnification using a Leitz Dialux 20 microscope by DV. The total number of cells was counted for each monoclonal using a 1 mm Index graticule (Graticules Ltd, Tonbridge, Kent, UK) and the number of blood vessels was counted per high power field. The number of cells and blood vessels per mm² of tissue was then calculated. Only sections in which both the epidermis and the dermis were identified were assessed. A coefficient of variation of less than 8·80% was obtained for the quantification of cell types and blood vessels.

STATISTICAL ANALYSIS
Differences between the mean number of cells and vessels in the tissues were assessed using the Wilcoxon signed rank test. Correlations were calculated using Spearman rank coefficient of correlation.

Results
INCREASED B-CELLS IN THE INFILTRATE OF PATIENTS WITH PA
There was a B-cell infiltrate demonstrated in the dermis of 14 of the 15 patients with PA. In one patient, B-cells were identified infiltrating the epidermis from a dermal papillae (fig 1). No B-cells were present in the dermis in four out of five controls with Ps or in any of the controls with normal skin. A small number of B-cells was present in the skin biopsy of one patient with Ps. The mean (SE) number of cells per mm² of B-cells in the dermal infiltrate was significantly greater in PA compared with Ps and with normal controls (15·9 (4·3) ± 1·5

**Table 1 Monoclonal antibodies: source, antigen recognised and respective specificity**

<table>
<thead>
<tr>
<th>Monoclonal Antibody</th>
<th>Source</th>
<th>Antigen</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>T3</td>
<td>DAKO</td>
<td>CD3</td>
<td>All T cells</td>
</tr>
<tr>
<td>T4</td>
<td>DAKO</td>
<td>CD4</td>
<td>Helper T cells</td>
</tr>
<tr>
<td>T8</td>
<td>DAKO</td>
<td>CD8</td>
<td>Suppressor/ cytotoxic T cells</td>
</tr>
<tr>
<td>UCHL1</td>
<td>DAKO</td>
<td>CD45Ro</td>
<td>Memory T cells</td>
</tr>
<tr>
<td>Mac 387</td>
<td>DAKO</td>
<td>LI</td>
<td>Monocytes</td>
</tr>
<tr>
<td>Leu-43</td>
<td>BD</td>
<td>CD14</td>
<td>Monocytes</td>
</tr>
<tr>
<td>L30</td>
<td>DAKO</td>
<td>CD20</td>
<td>B cells</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>DAKO</td>
<td>Class II</td>
<td>B cells/ Activated T cells</td>
</tr>
<tr>
<td>FVII-Rag p155</td>
<td>DAKO</td>
<td>FVII-Rag</td>
<td>Endothelial cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Monocytes/ Langerhans cells</td>
</tr>
</tbody>
</table>

Dako = Dakopatts (Copenhagen, DK), BD = Becton-Dickinson (Sunnyvale, CA, USA), *gift from Dr Alex Whelan.
INCREASED CD45RO T-CELLS IN PA

T-cells, as demonstrated by the CD3 marker, were the most abundant inflammatory cells in the dermal infiltrate of both Ps and PA. Most of these cells were also CD4+ (fig 2) and CD45Ro+ indicating that they were memory T-cells. In comparison to Ps, the patients with PA had significantly more CD45Ro T cells/mm² [mean (SE), 396-6 (176.4) v 161.5 (37.6); p = 0.02]. Most of the remaining mononuclear cells were monocyte/macrophage in origin as they stained positive with the Mac387, p155 and CD14 monoclonal antibodies. There was no significant difference in the number of monocytes between psoriatic patients with and without arthritis.

HLA-DR+ KERATINOCYTES OCCUR BOTH IN PA AND IN PS

While there were significantly more HLA-DR+ cells/mm² in PA epidermis compared with Ps [161-7 (25.7) v 90-9 (18); p = 0.02], there was no significant difference in the number of HLA-DR+ cells/mm² in PA epidermis compared with the normal controls (table 3). To assess which epidermal cells were HLA-DR+, serial sections of skin from three patients with PA and three controls with Ps were examined using a marker for HLA-DR, CD3 and the Langerhan's cell marker p155. HLA-DR+ cells which were negative for CD3 and p155 and thus consistent with keratinocytes were demonstrated in the epidermis from involved skin in patients with PA (fig 3) as well as in patients with Ps (fig 4).

VASCULARITY IN PA AND PS

The number of blood vessels was assessed in all sections of skin and the mean number of vessels per mm² of tissue calculated. There were significantly more blood vessels in PA and Ps skin compared with normal controls [PA: 112 (17), Ps: 77 (18), Controls: 51 (7); p = 0.02]. The number of vessels in the patients with PA tended to be greater than in Ps although the difference did not reach statistical significance.

Discussion

In this study, a small but significant number of B cells was demonstrated in the involved skin of 14/15 patients with PA. In contrast, no B cells were found in 4/5 patients with Ps or in 4/4 normal control skin specimens. While CD4+ CD45Ro+ T-cells accounted for the majority of cells in the dermal infiltrate in both PA and Ps, there were significantly greater numbers of activated T cells in PA skin compared to Ps and to normal controls.

Table 2 Relationship between the presence of dermal B-cells and arthritis

<table>
<thead>
<tr>
<th>Patients (n)</th>
<th>B-cell infiltrate in involved skin present</th>
<th>Absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA (15)</td>
<td>14†</td>
<td>1</td>
</tr>
<tr>
<td>Ps (5)</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Normal (4)</td>
<td>0</td>
<td>4</td>
</tr>
</tbody>
</table>

†p = 0.02.

Table 3 Epidermal HLA-DR+ cells in PA, Ps and normal controls

<table>
<thead>
<tr>
<th>Patients (total No)</th>
<th>Epidermal HLA-DR+ cells/mm² (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA (15)</td>
<td>161-7 (25-7)*</td>
</tr>
<tr>
<td>Ps (5)</td>
<td>90-9 (18)</td>
</tr>
<tr>
<td>Normal (4)</td>
<td>149-2 (41-8)</td>
</tr>
</tbody>
</table>

*p = 0.02 PA vs Ps.
Immunohistochemical markers for arthritis in psoriasis

Furthermore, in a subgroup of patients in which serial sections of skin were examined, HLA-DR+ keratinocytes were identified in the epidermis of psoriasis patients with or without arthritis. Finally, the number of dermal blood vessels was significantly increased in both PA and Ps patients compared with controls.

The finding of a sparse B cell infiltrate with some plasma cells in PA skin is interesting. Psoriasis is not generally associated with B cell hyperactivity although autoantibody production has been reported. Indeed, PA is characterised by the absence of rheumatoid factor in the serum helping to distinguish the condition from rheumatoid arthritis (RA). However, B cells with plasma cells are abundant in PA synovium where they may form focal infiltrates similar to those seen in RA. Thus B cells do appear to play a role in PA and further studies of B cell function could prove rewarding.

T cells, predominantly T helper (CD4+) cells, have previously been described to represent the majority of the cells in the dermal infiltrate in Ps and may persist in the chronic psoriatic plaque. Many T cells in psoriatic skin express the class II HLA-DR antigen and these cells have been shown to increase in the dermis and infiltrate the epidermis during early development of a psoriatic lesion. Further evidence for T cell involvement in the pathogenesis of psoriasis is suggested by the observations that cyclosporin A, a drug which inhibits T cell activation, may lead to remission of the skin disease and clearance of severe psoriasis has been described after allogenic bone marrow transplantation.

In the present study, the findings confirm previous reports of a predominant T cell infiltrate, these cells expressing the HLA-DR and CD45Ro antigens indicating that they are memory T cells in a post-activation state. Greater numbers of CD4+ CD45Ro+ T cells are seen in PA skin compared with Ps and this...
may reflect the intensity of adhesion molecule expression as both vascular cell adhesion molecule (VCAM)-1 and endothelial leukocyte adhesion molecule (ELAM)-1 appear to bind memory T cells preferentially and the latter is known to be up-regulated in psoriatic skin.

Langerhan's cells are found in normal skin forming a close network of interdigitating cells in the stratum Malpighii. It was initially suggested that the number of Langerhan's cells was increased in psoriasis. However, a number of studies have now shown a reduction in overall number and an altered distribution pattern of epidermal Langerhan's cells in psoriasis. It has been suggested that these cells now migrate to the dermo-epidermal junction. More recently, it has been suggested that there is a marked increase in the frequency of PA in psoriasis patients whose keratinocytes express HLA-DR antigen, identified as epidermal cells staining with a monoclonal for HLA-DR but not for OKT6. The possibility that some of these cells might represent activated T cells or B cells was not considered. Previous studies have demonstrated that the presence of HLA-DR+ keratinocytes is by no means specific to psoriasis being found in a number of other dermatoses including lymphocytic vasculitis, lupus erythematosus, morphea and many more. In this study, HLA-DR+ keratinocytes are seen in patients both with PA and Ps although more abundant in those with PA. Thus the association of DR+ keratinocytes with PA is quantitative and not absolute as previously suggested.

Vascular abnormalities have been described in both the skin and synovium in psoriasis. Braverman extensively examined the microcirculation in psoriatic skin and described prolongation and dilatation of the dermal capillary loops. In addition, ultrastructural abnormalities in the blood vessels were seen on electron microscopy with the development of venous-like capillaries with bridged fenestrations. Similar changes in vascularity have been described in the synovial membrane in PA. These studies, however, have not been quantitative and a comparison of the vascularity of PA and Ps skin has not been previously undertaken. In this study, psoriatic skin is shown to be more vascular compared with control specimens with a trend towards more blood vessels in the skin from PA subjects compared with those with psoriasis alone.

In conclusion, the present study has identified quantitative immunohistochemical differences in the skin from patients with PA compared with skin from patients with psoriasis alone. It is suggested that the presence of a B-lymphocytic infiltrate, increased CD45RO+ T-lymphocytes and increased HLA-DR+ keratinocytes are indicators of a more active inflammatory process and act as markers for arthritis in psoriasis.

This study was funded by a grant from The Charitable Infirmary Charitable Trust.

References:


Immunohistochemical markers for arthritis in psoriasis.

D J Veale, L Barnes, S Rogers and O FitzGerald

doi: 10.1136/ard.53.7.450

Updated information and services can be found at:
http://ard.bmj.com/content/53/7/450

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/